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7.  ABSTRAK 
 
PROFIL KLINIKAL DAN MAKMAL BAGI PENDERMA DARAH DENGAN 
ERYTHROSITOSIS. 
 
Dalam perubatan transfusi, setiap penderma darah adalah diwajibkan untuk menjalani ujian 
pengesanan terhadap nilai hemoglobin (Hb) mereka terlebih dahulu sebelum prosedur 
pendermaan darah. Mengikut amalan semasa, penderma darah yang didapati mempunyai 
nilai Hb yang tinggi turut dikecualikan daripada pendermaan darah. Tiada perhatian khusus 
diberikan terhadap penderma sedemikian walaupun umum mengetahui bahawa nilai Hb 
yang tinggi mungkin menunjukkan adanya patologi yang tersembunyi. Oleh sebab itu, 
tujuan kajian ini adalah untuk menilai kemungkinan etiologi yang berkaitan dengan 
erythrositosis dikalangan penderma darah.  
 
Satu kajian silang rentas telah dijalankan di Hospital Sultanah Aminah Johor Bahru 
(HSAJB) dan Hospital Universiti Sains Malaysia Kubang Kerian (HUSM) dalam tempoh 
sembilan (9) bulan dimana melibatkan penderma darah dengan pra-pendermaan nilai Hb 
yang tinggi. Sebanyak 175 sampel penderma telah dikumpulkan dan dianalisa untuk ujian 
hematologi, analisa Hb, ferritin, ujian biokimia serta kajian molekular bagi mengesan 
mutasi JAK2 V617F. Semua data dianalisa dengan menggunakan perisian SPSS versi 23.0. 
 
Prevalens penderma darah yg didapati mempunyai nilai Hb yang tinggi adalah 7.8% 
(n=175). Di antara 175 orang penderma darah, 103 penderma didapati mempunyai 
erythrositosis relatif, dimana kebanyakannya mungkin disebabkan oleh pengecutan isipadu 
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plasma berpunca daripada dehidrasi. Sebaliknya, tujuh puluh dua (72) penderma lain adalah 
didapati mempunyai erythrositosis mutlak. Sebanyak empat puluh sembilan (49) penderma 
didapati mempunyai latar belakang sebagai perokok kronik. Kami mendapati bahawa 
adanya hubungan antara status merokok dan talasemia/ hemoglobinopati dengan 
erythrositosis di kalangan penderma darah. Kami juga mendapati hubungan yang positif 
antara bilangan pendermaan darah dengan tahap erythrositosis (r=0.201). Semakin tinggi 
bilangan pendermaan darah, semakin tinggi nilai Hb yang akan didapati pada penderma 
tersebut. 
 
Kesimpulannya, nilai Hb yang tinggi dikalangan penderma darah menunjukkan etiologi 
patologi yang tersembunyi.  Beberapa penderma didapati mempunyai masalah perubatan 
seperti talasemia/ hemoglobinopati dan kekurangan zat besi. Kami juga ingin 
mencadangkan bahawa penderma darah dengan nilai Hb yang tinggi perlu disiasat dengan 
lebih teliti untuk memastikan penderma ini tidak mengidapi sebarang penyakit serius yang 
berkaitan dengan erythrositosis. 
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8.   ABSTRACT 
 
CLINICAL AND LABORATORY PROFILES OF BLOOD DONORS WITH 
ERYTHROCYTOSIS 
 
In blood banking setting, every blood donors are mandatory to have their haemoglobin 
(Hb) values tested before blood donation procedure. In current practice, donors with high 
Hb will be deferred from blood donation. Little attention is given to blood donors with high 
Hb although is it known that high Hb may indicate an underlying hidden pathological 
condition. Therefore, the aim of this study is to evaluate the possible underlying aetiologies 
associated with erythrocytosis in blood donors.  
 
A pilot cross sectional study was conducted in Hospital Sultanah Aminah Johor Bahru 
(HSAJB) and Hospital Universiti Sains Malaysia Kubang Kerian (HUSM) over nine-month 
period involving blood donors with high pre-donation Hb. A total of 175 samples were 
collected and analysed for haematological tests, Hb analysis, serum ferritin, biochemical 
tests and molecular study for the detection of JAK2 V617F mutation. All of the data were 
analysed using SPSS software version 23.0. 
 
The prevalence of blood donors with erythrocytosis was 7.8% (n=175). Among 175 donors, 
103 donors were found to have relative erythrocytosis, which mostly contributed by 
contraction of plasma volume possibly due to dehydration. Another seventy-two (72) 
donors had absolute erythrocytosis. A total of forty-nine (49) donors had background 
history of chronic cigarette smoking.  
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We found that there were associations between smoking and thalassaemia/ 
haemoglobinopathy with erythrocytosis in blood donors. We also found positive correlation 
between the numbers of blood donation with the degree of erythrocytosis (r = 0.201). The 
higher the number of blood donations, the higher Hb level will be observed. 
 
In conclusion, high Hb in blood donors does indicate hidden pathological aetiology. Quite a 
number of donors were found to have other significant medical conditions such as 
thalassaemia/haemoglobinopathy and iron deficiency state. We also strongly suggest that 
blood donors with high Hb level should be investigated thoroughly in order to exclude any 
significant pathological conditions that are associated with erythrocytosis. 
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 Objective: The aim of this study is to evaluate the possible underlying aetiologies 
associated with erythrocytosis in blood donors.  
 
 Patients and Methods: A pilot cross sectional study was conducted in Hospital 
Sultanah Aminah Johor Bahru (HSAJB) and Hospital Universiti Sains Malaysia Kubang 
Kerian (HUSM) over nine-month period involving blood donors with high pre-donation Hb. 
A total of 175 samples were collected and analysed for haematological tests, Hb analysis, 
serum ferritin, biochemical tests and molecular study for the detection of JAK2 V617F 
mutation. All of the data were analysed using SPSS software version 23.0. 
 
 Results: The prevalence of blood donors with erythrocytosis was 7.8% (n=175). 
Among 175 donors, 103 donors were found to have relative erythrocytosis, which mostly 
contributed by contraction of plasma volume possibly due to dehydration. Another seventy-
two (72) donors had absolute erythrocytosis. A total of forty-nine (49) donors had 
background history of chronic cigarette smoking. We found that there were associations 
between smoking and thalassaemia/ haemoglobinopathy with erythrocytosis in blood donors. 
We also found positive correlation between the numbers of blood donation with the degree of 
erythrocytosis (r = 0.201). The higher the number of blood donations, the higher Hb level 
will be observed. 
 
 Conclusion: High Hb in blood donors does indicate hidden pathological aetiology. 
Quite a number of donors were found to have other significant medical conditions such as 
thalassaemia/haemoglobinopathy and iron deficiency state. We also strongly suggest that 
blood donors with high Hb level should be investigated thoroughly in order to exclude any 
significant pathological conditions that are associated with erythrocytosis. 
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1.0 GENERAL INTRODUCTION 
 
Erythrocytosis is defined as an increased in the amount of erythrocytes in the whole 
blood.  It is suspected when the individual presented with a haemoglobin (Hb) or 
haematocrit (HCT) above the normal reference range (i.e. Hb level is above 18.5 g/dL 
or the packed cell volume (PCV)/ HCT is greater than 0.52 in male; or 16.5 g/dL and 
0.48 in female respectively) (Keohane et al., 2013).  
 
Polycythaemia and erythrocytosis is frequently used synonymously. Traditionally, the 
term polycythaemia refers to a cluster of disorders, typically characterized by a 
persistent elevation in HCT due to increased in erythrocytes in the blood circulation  
(Hoffbrand and Moss, 2011). However, polycythaemia may also be referred to the 
clonal disorder, such as polycythaemia vera (PV), in which all three haematopoietic cell 
lineages are involved causing erythrocytosis, frequently with leukocytosis and 
thrombocytosis (McMullin et al., 2005). When only red cell lineage is affected, thus the 
term erythrocytosis is more appropriate compared to polycythaemia. 
 
The classification of erythrocytosis depends on the results of a Red Cell Mass (RCM) 
measurement, in which the results will separate them into two different groups; the 
absolute erythrocytosis in which both HCT and RCM are above the predicted normal 
reference range, and the relative erythrocytosis in which the HCT is high but the RCM 
is in the normal reference range. However, this definition is based on a mutual 
definition of a raised packed cell volume or HCT and a raised RCM (McMullin, 2008). 
The possible aetiology for an absolute erythrocytosis can be divided into primary 
causes, in which there is an intrinsic problem in the bone marrow resulting in increased 
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erythroid production, or secondary causes; where there is an event outside the bone 
marrow which accelerates the process of erythropoiesis. The remaining are classify as 
unexplained group idiopathic erythrocytosis (McMullin, 2008). 
 
Individuals who were found to have high RCM and following investigations do not 
fulfilled any criteria of primary or secondary erythrocytosis were known as idiopathic 
erythrocytosis (IE) (Messinezy and Pearson, 1999). 
 
In general, whole blood donation does not cause significant changes in the blood count 
parameters as blood cells will be replenished quickly by bone marrow approximately 
around duration of four to eight weeks.  For this reason, subsequent donation also will 
be allowed at least 8 weeks apart from the previous blood donation. Haematinics tablets 
and advice on iron-rich diet also will be given post-donation to prevent the development 
of iron deficiency anaemia due to repeated donation especially in regular blood donors. 
Therefore, blood donors are expected to have normal blood count parameters during 
subsequent donation. 
 
In blood banking setting, blood donors are mandatory to have their Hb values tested 
regularly before blood donation procedures in order to exclude anaemia, which is the 
most frequent cause for temporary deferral. However, it is not uncommon to observe Hb 
value above or near to the upper limit of normal reference range. In current Malaysian 
transfusion medicine practices, all blood donors with high Hb (more than 18 g/L) will 
be deferred from donation. 
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In current practice, less attention is paid to blood donors with high Hb or at upper limit 
level of Hb compared to the anaemic donors although is it known that high Hb may be a 
sign of a disease and a risk factor for vascular accidents. One of the reasons may be due 
to donors appearing healthy and did not show any sign of diseases.  
 
However, the diagnosis and clinical assessment in such donors may be complicated by 
frequent, regular blood donations that can mask an underlying pathological disease such 
as Myeloproliferative Neoplasm (MPN) due to steady reduction of blood mass caused 
by the donations (Tagariello et al., 2009).  
 
The possibilities of erythrocytosis among blood donor include physiological variation, 
early phase of Polycythaemia Vera (PV) in which 10-15% will express obvious 
characteristics of the disease later, unrecognised congenital erythrocytosis, 
unrecognised secondary acquired erythrocytosis or recently undescribed form of 
primary or secondary erythrocytosis (Messinezy and Pearson, 1999). 
 
A study done at a hospital in Milan, Italy showed that around 8% of regular volunteer 
blood donors had high Hb and HCT level. This study also found that some donors with 
upper limit of Hb and HCT level prove to have underlying acquired pathological 
condition such as early stage of PV; a type of MPN, as well as respiratory failure. Thus, 
the study made a conclusion that some donors with upper limit Hb and HCT levels have 
hidden medical problems (Zanella et al., 1987). 
 
On the other hand, another study done on a group of patients with underlying MPN and 
found that 18.1% of the patients were or had been blood donors. Interestingly, there was 
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no other single feature except that blood donation was common in the past history of 
those patients. Because of that, the study highlighted on the importance of paying due 
attention to the blood cell count of the donors (Randi et al., 1994). 
 
Thus, it is hoped that this study will contribute as a part of health screening service for 
blood donors, functioning to detect or diagnose associated medical problems when 
having high Hb level and also can be considered to be included in the national 
guidelines on management of blood donors with erythrocytosis. 
 
Since there is no local data available on erythrocytosis in blood donors in Malaysia, it is 
hoped that the result of this study can be used as one of the referral data for such donors 
in future. 
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2.0  LITERATURE REVIEW 
 
2.1 Blood donation 
 
Blood donation can be categorized into two types namely as whole blood donation and 
apheresis donation. Whole blood donation means the whole blood is collected from the 
donor whereas in apheresis donation, only selected blood component is collected. 
Whole blood constitutes of red blood cells (RBCs), white blood cells (WBCs), platelet, 
plasma and few other components. It becomes the main source for the preparation of 
other blood components where the separation involves manual processing procedure 
under controlled temperature with specific centrifugation speed following the specific 
component processing guidelines. 
 
On the other hand, the word “apheresis” is originally come from the word “aphairesis”, 
a Greek word, which means “to separate,” “to take away by force,” or “to remove”. The 
process started with the withdrawal of whole blood from a donor, extraction of the 
desired component into a collecting blood bags through a filter membrane or by 
centrifugation method, and returning the other unused blood component back into the 
donor. Apheresis also can be used as a therapeutic method in some of the medical cases, 
act by removing specific pathologic components or substances from a patient’s blood 
for therapeutic purpose (Winters, 2012). 
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2.1.1 Donor selection and deferral 
 
Blood and blood component is one of the important treatment modalities and constantly 
on demand as they are used in many medical procedures. Thus, it is very important to 
ensure that the blood is safe for usage and come from the safe donors. In most of the 
countries in the world including Malaysia, blood supply is contributed by voluntary, 
non-remunerated blood donors. For that safety reason, blood donor criteria selection is 
created to screen and to ensure the individuals who fulfilled the criteria will only be 
accepted to donate blood (Eder et al., 2009). 
 
Deferral of the donors who are not fulfilled the selection criteria can occur at any stage 
of blood donation started from registration, during the blood donation or even after the 
blood donation. This precautionary measure was taken in order to protect both of the 
blood donors as well as patients whom received the transfusion. Pre-donation 
counselling particularly is conducted to assess donor eligibility, complemented by 
various blood unit testing which will be done later, contribute to the safety of the unit 
(Sandborg and Thornton, 1994).  
 
Pre-donation interview alone considered as one of the important preliminary measure to 
capture the possibility of window period for certain communicable diseases, 
automatically reducing the risk of disease transmission, especially in cases that being 
undetected by standard blood serology tests (Germain and Goldman, 2002).  
 
Individuals who do not eligible for blood donation will be deferred either temporarily or 
permanently depending on the cause of deferral. A temporary deferral can be as short as 
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twenty four hours to as long as two years, whereas permanent deferral refers to a blood 
donor who disqualified from blood donation indefinitely.  The commonly reported 
cause for temporary deferral are low pre-donation haemoglobin level, low or high blood 
pressure, underweight, taking medications (e.g. antibiotics), medical conditions (e.g. 
upper respiratory tract infection), minor or major surgical procedures (e.g. acupuncture, 
tattoo, dental procedures) (Germain and Goldman, 2002). 
 
The donor deferral rates vary from a blood donation centre to another, estimated around 
5% to 25%. In Malaysia, it is estimated around 15% to 20% of blood donors are 
reported to be deferred from blood donation in Pusat Darah Negara as well as 
throughout the countries every year. Most of them are temporarily deferred, and the top 
three listed for this deferral are contributed by low haemoglobin level, followed by high 
or low blood pressure. About 10% of donor deferrals are permanent deferral in which 
majority of them are due to high risk behaviour (Seong, 2013). 
 
Studies done in Hospital Universiti Sains Malaysia Kubang Kerian (HUSM) showed 
around 5.6% blood donors are deferred in this blood centre in year 2006, and the 
majority of them (64.1%) are regular donors. The study also reported the similar finding 
for the cause of deferral as Pusat Darah Negara, leads by low haemoglobin level 
(40.7%) with female donors dominating (69%) in this category. The second common 
cause are high blood pressure (29.4%), dominated by male donor which constitute 
around 45%. The other causes include medical illness (15.6%), low blood pressure 
(3.5%), short interval between donation (1.7%), polycythaemia (1.7%) and other causes 
of deferral (5.2%) (Rabeya et al., 2008). 
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A retrospective study done among Turkish population in 5 years starting from 2001 
until 2006 according to the gender, age and education level also showed quite identical 
findings in term of cause of donor deferral; low Hb (20.7%), medical condition such as 
upper respiratory tract infection (17.7%), hypertension (5.6%), polycythaemia (5.6%) 
with addition of high risk sex partner (16.7%) as top five listed in the whole group. The 
leading deferral reason in male donor is upper respiratory tract infection while in female 
donors is due to low level of haemoglobin. Interestingly, the education level of donors 
showed no effect on the rate of deferral for both genders at different age group (Arslan, 
2007). 
 
An individual who does not meet the blood donor selection criteria (e.g. low 
haemoglobin, low blood pressure) may experience adverse donor reaction such as 
headache, giddiness or fainting episode. They will be temporarily deferred with proper 
advised and encourage to return for blood donation after the deferral period (Halperin et 
al., 1998).  
 
On the other hand, blood donor will be permanently disqualified from blood donation 
due to medical conditions or due to their high risk behaviour and lifestyle (high risk 
groups). Donors with medical conditions such as malignancy, bleeding abnormality as 
well heart diseases are prohibited from blood donation as this process will potentially 
affect their well being, thus permanent deferral is indicated. High risk group (e.g. 
individuals with multiple sex partners, sex workers, and intravenous drug users) will be 
permanently deferred in view of risk of transmitting transfusion transmitted disease 
(Lim et al., 1993). 
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Permanent deferral could affect a donor psychologically, thus the purpose of donor 
deferral must be clearly explained considering it is the best interest for both blood donor 
and blood recipient. Understanding this will make it easier for a blood donor to accept 
the deferral, either temporary or permanent. Permanently deferred donors will be 
counselled appropriately and professionally by trained staff so that the reason of being 
permanently deferred can be accepted (Lim et al., 1993). 
 
Blood donor selection criteria are also regularly reviewed to improve the selection 
criteria and to prevent unnecessary donor deferral. Clearly, this selection guidelines help 
to avoid or reduce harm to the blood donors, identify any probable significant pathology 
in the donors, maximizing the therapeutic quality of the ultimate blood product as well 
as to prevent any damage to the recipient (Arslan, 2007). 
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2.2 Haematopoiesis 
 
Haematopoiesis is the production of blood cell components. The word haematopoiesis 
itself is derived from a Greek word meaning "blood" and "to make". In a healthy adult 
person, large numbers of new blood cells are produced (approximately 1011 –1012) 
everyday in order to sustain steady state levels in the peripheral circulation. The unique 
ability of pluri-, multipotent and lineage-committed cells give rise to the formation of 
different types of mature and functional blood cells via a cycle of proliferation and 
differentiation pathways. These stem cells will undergo asymmetric division, whereby a 
precursor cell must divide and expand in every stage of the process before further 
differentiating along a given pathway in order to maintain the steady-state levels of each 
cell type. Hematopoietic stem cells which are found in latent state in the bone marrow, 
forming the basis for this hierarchy and are maintained in steady numbers by self-
renewal properties (Durand and Dzierzak, 2005).  
 
Committed progenitor cells will be yielded and accumulated from pluripotent 
haematopoietic stem cells after a series of division. Although these cells preserve some 
stem cell-like properties, but their fate is more restricted towards a specific lineage 
evidenced by the possibility to isolate common lymphoid and myeloid progenitor cells 
that exhibit specific preferences to the lymphoid and myeloid lineages. Common 
lymphoid precursors will ultimately develop into T- and B- lymphocytes, whereas 
common myeloid precursors will differentiated into erythroid cells, megakaryocytes 
(Meg-E fate) or granulocytes and monocytes/macrophages (GM fate) respectively 
(Rosmarin et al., 2005). Over years, many studies has reported that development and 
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differentiation of haematopoietic cells are mediated by cytokines and their receptors 
(Ogawa, 1993). 
 
Interestingly, recent studies conducted over the past few decades have revealed that 
Janus Kinases (JAKs), a family of tyrosine kinase and their downstream transcription 
factors known as STATs (signal transducers and activators of transcription) have been 
demonstrated to responsible largely in signalling for the hematopoietic cytokine 
receptor. Therefore, any anomaly in these pathways, such as that is caused by the 
recently recognized JAK2V617F mutation, becomes an underlying cause for diseases 
such as leukaemias and other MPN. This recent discovery, when combined with the fact 
that STATs are activated by oncoproteins such as BCR-ABL, underscores the 
importance of the JAK-STAT pathway in both normal cellular development and disease 
states (Jatiani et al., 2010). 
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2.2.1 Janus Kinases (JAKs) and JAK/STAT pathway 
 
The blood cell production is tightly controlled by a number of growth factors and 
cytokines that influence the survival, proliferation and differentiation of cells. Most of 
these molecules attach to the receptors of the cell membrane, which belong to a family 
of closely related cytokine receptors that lack intrinsic catalytic activity but are closely 
related with tyrosine kinases of the Janus Kinase (JAK) family (Khwaja, 2006). 
 
Janus kinases were recognized as a unique family of cytoplasmic tyrosine kinase, 
comprises of four members known as JAK1, JAK2, JAK3 and TYK2. Each of them is 
composed of seven JAK homology (JH) domains divided into three specific domain, 
namely as typical kinase (JH1), JAK homology domain 2 (JH2), and regions of 
homology (JH3-JH7) that are found in the N-terminal half of the protein, which are 
exclusive among the JAK family (Figure 2.1) (Ihle and Gilliland, 2007).  
 
JH1 domain contains the catalytic activity of tyrosine kinase where as JH2 domain plays 
an important role as a negative kinase inhibitor on JH1 activity. Hence, any deletion or 
mutation occurs in JH2 will resulting in constitutive activation of the kinase. The JH2 
domain also mediates interaction with STAT family members that are targets of the 
JAK kinases (Khwaja, 2006). 
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 Figure 2.1: Structures of JAK2 and JAKV617F. 
 
(Adapted from (Ihle and Gilliland, 2007). 
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Like most of tyrosine kinase, the activity of the JAKs is also tightly regulated and 
phosphorylation process is necessary within the activation loop of the kinase to attain a 
significant catalytic activity level. At the moment, JAK2 is the only JAK family 
member acknowledged so far to be implicated in human leukaemia (Valentino and 
Pierre, 2006). 
 
Transcription factors known as STAT proteins (Signal Transducers and Activators of 
Transcription) were essential in mediating almost all cytokine driven signalling. These 
proteins are remaining latent in the cells’ cytoplasm and their activation and function 
are described in Figure 2.2. In normal cells, activation of the STATs via ligand binding 
is a temporary event whereby in many neoplastic cells, the STAT proteins are 
persistently activated. (Bromberg and Darnell Jr, 2000).  
 
The JAK2/STAT pathway has a significant responsibility in controlling cell 
proliferation, activation and apoptosis. Therefore, congenital deficiencies in JAK-STAT 
signalling are associated with immunodeficiency states whereas any acquired mutations 
and translocations that causing its activation are involved in the pathophysiology of 
haematological disorders (Jatiani et al., 2010).  
 
Recently, STAT phosphorylation and its activation are found can be mediated by a 
number of non-receptor tyrosine kinase such as via oncogenes ; src and abl (Bromberg 
and Darnell Jr, 2000). 
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Figure 2.2:  The JAK-STAT signalling pathway. Following attachment of a ligand to its 
receptor, receptor-associated JAKs become and mediated phosphorylation of specific 
receptor tyrosine-kinase residues. This leads to the recruitment of specific STATs which 
are then also tyrosine phosphorylated. Activated STATs are released from the receptor, 
undergo dimerization and translocate to the nucleus, finally bind to specific regulatory 
sequences to activate or repress the transcription of target genes. Thus, the JAK/STAT 
cascade provides a direct mechanism for translating an extracellular signal into a 
transcriptional response. 
(Adapted from (Schindler, 2002)). 
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2.2.2 JAK2 V617 mutation 
 
JAK2 gene is one of the member of the Janus kinase family. It can be found on 
chromosome 9, encodes for JAK2 protein. The normal JAK2 protein is a cytoplasmic 
tyrosine kinase, which associated with cytoplasmic domain of haematopoietic growth 
factors and cytokines such as erythropoietin, thromboietin, interleukin-3 (IL-3), 
granulocytes colony stimulating factors (G-CSF) and granulocyte macrophage colony 
stimulating factors. In other word, it functions as an intermediate between membrane 
receptors and signalling molecules in the cell signalling pathway. When these molecules 
bind to their respective receptors, dimerization of the subunits occurs, causing the JAK2 
are brought in proximity and undergo transphosphorylation causing its activation 
(Baxter et al., 2005). 
 
Clonal, acquired point mutation of JAK2 gene, leads to substitution of Valine-to-
Phenylalanine at amino acid 617 (V617F) due to replacement of Guanine (G) by 
Thymine (T) in the nucleotide sequences (1848 G > T), causing constitutive activation 
of the tyrosine kinase that is believed to confer erythropoietin-independent 
hypersensitivity and erythropoietin-independent survival to the myeloid-stem cell. Thus, 
mutation in the JAK2 causing that this kinase remain active even without the growth 
factors stimulation resulting in continuous proliferation of mature cells. Many studies 
show JAK2 mutation has been found in the majority of patients with PV and also in 
other MPN. A point mutation in the JAK2 gene was identified in several MPN, most 
frequently in Polycythaemia Vera (65-97%), Essential Thrombocythaemia (23-57%) 
and Myelofibrosis (35-57%). It is also occasionally present in Myelodysplastic 
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Syndrome, Chronic Myelomonocytic Leukaemia and other atypical myeloid disorders 
(Ihle and Gilliland, 2007). 
 
Some studies demonstrated that JAK2 mutation is more common that MPN and can be 
found in other patients with non-haematological disorders. Interestingly, most of the 
JAK2 mutation carriers have the same finding on blood cell parameters; normal red cell 
count but significantly higher in leukocytes and platelet counts although most were 
within the normal reference limit. Its presence may be useful for the early identification 
of haematological disorders but may not be used exclusively for the diagnosis of MPN 
(Xu et al., 2007). 
 
Detection of JAK2 mutation also at very low level in healthy individuals who have 
perfectly normal blood count is also reported in few studies. Thus, the conclusion made 
that this type of mutation is probably unrelated with the progression of the disease but 
its present may indicates that a very early molecular event has occurred prior to the 
manifestation of haematological disorders, especially MPN phenotype. This mutational 
event itself may not adequate enough to provoke MPN. This study data was supported 
by the finding of low annual incidence of MPN reported compared to the frequency of 
individuals harbouring JAK2 mutation (Sidon et al., 2006). 
 
Interestingly, the prevalence and the frequency of JAK2 mutation also was found higher 
in smokers compare to non smokers population, contributed by the acceleration of 
erythropoiesis which causing the haematopoietic cells susceptible to JAK2 mutation. 
However, there is no correlation can be concluded between the prevalence of the JAK2 
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mutation or the frequency of the mutation with RBC, HCT or WBC count (Weinberg et 
al., 2012). 
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2.3 Erythrocytosis 
 
Erythrocytosis encompasses a number of disorders characterized by increased 
circulating red blood cells (RBCs) which can be classified into relative, absolute and 
idiopathic erythrocytosis (McMullin, 2008).  
 
Relative erythrocytosis refers to a condition in which the HCT is elevated, normal 
RCM, while the plasma volume may be reduced. It is associated with various events 
such as acute hypoxia, cigarette smoking, excessive alcohol intake and the usage of 
diuretics (Biswas et al., 2003). 
 
Absolute erythrocytosis can further divided into primary and secondary forms (Table 
2.1). Primary erythrocytosis are characterized by expanding of erythropoietic 
compartment independent of erythropoietin (EPO) and/or abnormally increased in the 
response of the haematopoietic precursors to EPO due to hereditary or acquired somatic 
mutations. On the other hand, in secondary erythrocytosis, the erythroid precursors 
show normal responsiveness towards erythropoietin, but there are increased in the levels 
of circulating factors driving erythropoiesis (most commonly erythropoietin, insulin 
growth factor I, angiotensin II/angiotensin receptor axis aberrations and cobalt) (Finazzi 
et al., 2006). 
 
Secondary erythrocytosis may come up from several causes including inappropriate 
erythropoietin production, renal tumours and other kidney diseases, but association with 
defective oxygen transport is rare and usually caused by abnormal Hb with increased 
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oxygen affinity. Most patients with this condition appear in good health but had higher 
than normal RBC and Hb levels in the blood (Prakobkaew et al., 2010). 
 
Secondary erythrocytosis associated with thalassaemias and haemoglobinopathies is 
also rare, and among those which produce erythrocytosis, only moderate degrees of 
elevation of Hb and RBC counts have generally been found (Bessman, 1977; Fairbanks 
et al., 1979). 
 
Idiopathic erythrocytosis (IE) constitutes the remaining group of individuals in whom 
the cause for absolute erythrocytosis has not yet been identified. In other words, it is 
defined as an increased in RCM without an identified cause, i.e. the underlying cause 
for acceleration in erythropoiesis is unknown. Its diagnosis is based on the exclusion of 
various primary or secondary polycythaemias (congenital or acquired). Heterogenous 
mechanisms underlying IE have been suggested, including early stage of PV and 
unrecognized congenital or secondary polycythaemia (Messinezy and Pearson, 1999). 
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Table 2.1: Pathophysiological classification of absolute erythrocytosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Adapted from (McMullin, 2008). 
 
 
 
Primary polycythaemia: 
 Congenital 
 Primary familial congenital polycythaemia (including mutations of 
the EPO receptor) 
 Acquired 
 Polycythaemia Vera 
Secondary erythrocytosis: 
 Congenital 
 Mutant high oxygen-affinity haemoglobins 
 Congenital low 2,3-biphosphoglycerate deficiency 
 Methaemoglobinaemia 
 Chuvash polycythaemia and other VHL mutations ( with some 
features of primary polycythaemia) (autonomus high EPO 
production) 
 Acquired 
 Hypoxaemia (chronic lung disease, high altitude, cyanotic 
congenital heart disease) 
 Renal disease (tumours, cysts, hydronephrosis, renal artery 
stenosis, renal transplantation) 
 Tumours (cerebellar haemangioblastoma, phaechromocytoma, 
paraganglioma, uterine fibroids) 
 Drugs (erythropoietin, androgens) 
Idiopathic erythrocytosis 
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2.4 Primary erythrocytosis 
 
Primary erythrocytosis is applied when there is an intrinsic defect of the erythroid 
component in the bone marrow. It can be classified into congenital and acquired cause. 
However, the major cause of primary erythrocytosis is Polycythaemia Vera (PV) in 
which the marrow producing too many erythrocytes, and commonly with increased in 
granulocytes as well as platelets (McMullin, 2008). 
 
2.4.1 Congenital causes 
 
Erythrocytosis due to congenital causes are those in which an underlying genetic 
abnormality has been recognized. The usual presentation is at a younger age as the 
mutation has been exist since birth with positive family history of erythrocytosis as the 
defect is inherited although possibility of new mutations can arise. Mutation of 
erythropoietin receptor (EPOR) gene is rare but presented as one of the causes that can 
give rise to congenital erythrocytosis (Percy et al., 1998). 
 
Physiologically, the hormone EPO binds to its receptor on the cell surface, and initiates 
a series of events  in which other proteins are recruited, phosphorylated and translocated 
to the nucleus, leads to gene transcription where a further signal results in increased  
erythropoiesis. Inhibition of this process will take place whenever sufficient 
erythrocytes have been produced, mediated by the attachment of the SHP-1 protein to 
the EPOR, which dephosphorylates the receptors (de La Chapelle et al., 1993). 
 
